Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation

Mingming Qu1,2 · Qiang Liu1,2 · Hong-Guo Zhao3 · Jun Peng1,2 · Heyu Ni4,5,6,7 · Ming Hou1,2 · A. J. Gerard Jansen8,9

Received: 24 July 2017 / Accepted: 7 May 2018 / Published online: 18 May 2018
© The Author(s) 2018

Abstract
Infectious complications are common and sometimes life threatening in patients with immune thrombocytopenia (ITP), mainly due to the immune-suppressive therapy. Recent evidence suggests a potential role of platelets in the inflammation process. In this clinical study, we further investigated the role of thrombocytopenia on infections in patients with primary ITP. We retrospectively evaluated data from the recently published large randomized clinical trial of a cohort of 195 patients with primary ITP, who were randomized for prednisone or high-dose dexamethasone. From 158 patients (81%), data on platelet count and infections within the first month of treatment were collected. In this period, 24% of the ITP patients had an infection. Patients with infection had significantly lower platelet counts during the first month of treatment leading to a significant lower therapy response at 1 month and a significant longer hospital stay (14.0 versus 9.8 days). Additionally, Cox regression analysis showed that an increase in platelet count of 20 × 10^9/L led to a reduction of 52% in infections in the next week, showing low platelet count is a significant risk factor for infection. Platelet transfusion led to an increase in platelet count in ITP patients without infection, but not in patients with infection. In conclusion, infections are common in patients with primary ITP leading to significant worse response rates and a longer hospital stay. Interestingly, low platelet count was independently correlated with an increased risk of infection.

Keywords ITP · Infection · Platelet transfusion · Thrombocytopenia

Introduction

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by autoantibody-induced platelet destruction and decreased platelet production often resulting in mild bleeding symptoms (e.g., petechiae) to severe bleeding manifestations (e.g., intracranial hemorrhage) [1, 2]. Diagnosis is made by exclusion of other causes of the thrombocytopenia, e.g., infections. In patients with chronic ITP, infections are common, with major morbidity and mortality [3, 4]. It is mainly considered that treatment of ITP increases the risk of infections (e.g., corticosteroids, and other immunosuppressive agents). However, recently, it is shown that infection is not only related to the immunosuppressive treatment in chronic ITP but also to the etiology of the disease itself [5]. New studies show that platelets play a role in the immune response,
but knowledge of the clinical importance is still limited, especially in primary ITP patients [6–10]. To further elucidate the role of platelets in risk of infection, we analyzed data of a cohort of primary ITP patients from the recently published prospective randomized multicenter clinical trial of Wei et al. [11].

**Materials and methods**

**Study design**

In the prospective, multicenter, randomized, controlled, open-label clinical trial of Wei et al., newly diagnosed ITP patients were randomized for high-dose dexamethasone (HD-DXM) or prednisone (PDN) for first-line management [11]. Patients in the HD-DXM arm received DXM orally at 40 mg for 4 consecutive days and then stopped. If platelet count remained low (< 30 × 10⁹/L) or there were bleeding symptoms by day 10, an additional 4-day course of DXM (40 mg daily) was given. Patients in the PDN arm received PDN orally at 1.0 mg/kg body weight daily for four consecutive weeks. No dose adjustments were made so all patients in both groups received the intended and same dose of immunosuppressive therapy. Platelet count was measured according routine local laboratory practice at days 0, 7, 14, 21, and 28 after randomization. The study was conducted in collaboration among nine separate investigation sites in China. Data were collected from each participating site and sent to the principal investigation site at Qilu Hospital, Shandong University, for analysis. The study protocol was approved by the ethics committee on medical research of each participating site. All patients provided written informed consent in accordance with the Declaration of Helsinki before enrollment.

**Patients**

Inclusion criteria were patients with primary ITP, without prior treatment. Exclusion criteria were seropositive detection of HIV, hepatitis B virus or hepatitis C virus, pregnancy or lactation, active infection, hypertension, diabetes, cardiovascular diseases, liver and kidney function impairment, psychosis and osteoporosis, and life-threatening bleeding (e.g., massive hemorrhage with severe anemia, central nervous system bleeding). No prophylactic antibiotics were given during first month of treatment with steroids.

**Infections**

Primary outcome in the study of Wei et al. was initial response and sustained response based on platelet counts. As adverse event, three infections were measured in this study [11]. Definition of infection was different than ours; they measured only severe infections caused by immunosuppressive therapy (e.g., one patient terminated immunosuppressive therapy due to infection). As our focus is on the role of platelets on infection, we used a different, broader, definition for infections. In our study, infections with a grade 2 or more were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) grading scale (version 4.03: June 14, 2010), including viral, bacterial, and fungal episodes.

**Statistical analysis**

Baseline characteristics were summarized using descriptive statistics. Continuous variables were summarized as median or mean ± standard deviation or standard error of the mean, and categorical variables were summarized using frequencies and percentages. Differences between the groups were analyzed with t tests or with nonparametric Mann-Whitney test when not normally distributed. To evaluate the relationship between platelet count and infections, we used Spearman correlation coefficient. To adjust for time of infection, we used Cox regression analysis with platelet count as time-varying covariate; platelet counts were categorized into groups of 20 × 10⁹/L, and the last platelet count before the time of occurrence of infection was used for analysis, e.g., when infection occurred at 10 days after randomization, the platelet count from day 7 was used. Risk of infection was presented as hazard ratio. All p values are two-sided, and p values < 0.05 were considered statistically significant.

**Results**

**Baseline characteristics**

Between January 2011 and May 2014, 261 patients were screened for eligibility and 195 patients with primary ITP were randomized in the study of Wei et al. [11]. From this patient population, data on platelet count and infection of 158 patients could be collected retrospectively. In the first month after randomization, infection occurred in 24% of the patients: 120 patients had no infection and 38 patients had a viral or bacterial infection. Baseline characteristics of both patient groups are summarized in Table 1. There were no differences in age, sex, antibodies, and type of treatment. Except for leucocyte count at t = 0, no differences were found for blood values between the two study groups. Usage of type of steroids was similar for both groups.
Infection leads to lower response rates and prolonged hospital stay

Mean platelet counts during the first month after randomization are shown for patients with and without infection in Fig. 1. Platelet count at \( t = 0 \) was the same for both groups: \( 13.8 \times 10^9/L \) for the patients without infection and \( 11.8 \times 10^9/L \) for the patients with infection (\( p > 0.05 \)) (Table 1). However, during the first month, patients with infection had significant lower platelet counts than patients without infections at 1, 2, and 4 weeks (\( p < 0.01 \)). Only, the lower platelet count at 3 weeks for the patients with infection was not statistically significant. According to the response criteria of Rodeghiero et al., a significant lower response at 1 month is found for patients with infection as shown in Fig. 2 (\( p < 0.05 \)) [2]. Additionally, infection is also associated with a significant longer hospital stay, e.g., 9.8 ± 5.2 days for patients without infection and 14.0 ± 8.7 days for patients with infection (Table 1).

Fig. 1 Infection leads to lower platelet counts in patients with primary ITP. Mean platelet counts (± s.e.m.) during the first month after therapy in patients with primary ITP with and without infection. *\( p < 0.01 \)

### Table 1 Patient demographics and baseline characteristics

| Characteristic                        | Overall (N=158) | No Infections (N=120) | Infections (N=38) |
|---------------------------------------|-----------------|-----------------------|-------------------|
| Age (year)                            | 42±16           | 42±16                 | 42±16             |
| Sex (m/f)                             | 51/107          | 37/83                 | 14/24             |
| Hemoglobin value (mg/dL) at \( t = 0 \) | 123.2±28.6      | 122.1±30.8            | 126.8±20.1        |
| Leucocyte count (×10^9/L) at \( t = 0 \) | 7.7±3.4         | 7.2±3.2               | 9.1±3.6*          |
| Platelet count (×10^9/L) at \( t = 0 \) | 13.4±12.2       | 13.8±12.8             | 11.8±10.4         |
| Hemoglobin value (mg/dL) at \( t = 1 \) month | 125.5±32.2      | 124.0±23.9            | 130.4±50.3        |
| Leucocyte count (×10^9/L) at \( t = 1 \) month | 11.0±7.9        | 11.2±7.8              | 10.5±8.2          |
| Platelet count (×10^9/L) at \( t = 1 \) month | 87.7±78.7       | 107.4±79.7            | 25.4±24.3*        |
| Blood count (×10^9/L) at \( t = 0 \) | 3.9±3.4         | 3.8±3.5               | 4.1±3.2           |
| Duration hospital stay (days)         | 10.9±6.5        | 9.8±5.2               | 14.0±8.7*         |
| Treatment (dexamethasone/prednisone)  | 118/40          | 87/33                 | 31/7              |

Antibodies

|none| 46 | 35 | 11 |
|GPIb-IX| 13 | 11 | 2  |
|GPIIIa| 15 | 7  | 8  |
|Both| 18 | 16 | 2  |
|Unknown| 66 | 51 | 15 |

Type of infection

|Viral| 11 |
|Bacterial| 27 |

Time of infection (day)

|5.7±5.1|

Platelet transfusion

|Number of patients transfused| 91 (57.6%)| 62 (51.7%)| 29 (76.3%)|
|Total amount of units| 150 | 91 | 59 |
|Median amount of units| 1 | 1 | 1 |
|Mean| 1.0 | 0.8 | 1.6* |

Mean values for age, platelet count, leucocyte count, hemoglobin values, bleeding score, hospital stay, and time of infection ± standard deviations are shown. Bleeding score was calculated by adding the points relevant to various clinical bleeding signs as described by Wei et al. [11]

\*\( p < 0.01 \)
In both groups, none of the patients had a thrombotic event, e.g., deep venous thrombosis or pulmonary embolism, during the first month of treatment. At 1 month, no differences were found between patients with and without infection in mean hemoglobin value (124.0 vs 130.4 g/L, $p > 0.05$) and leucocyte count (11.2 × 10^9 vs 10.5 × 10^9/L, $p > 0.05$).

Low platelet count is correlated with increased risk of infection

As shown in Fig. 1, lower platelet counts led to more infections. Platelet count at 1 month was significantly correlated with infection with a Spearman correlation coefficient of $−0.517$ ($p < 0.01$). To further adjust for time of infection, we used Cox regression analysis with platelet count as time-dependent variable. Platelets were categorized into groups of 20 × 10^9/L, and the last platelet count before time of infection was used for analysis as was described in the “Materials and methods” section. A hazard ration of 0.52 was found meaning an increase in platelet count of 20 × 10^9/L leads to a significant reduction of 52% in chance of infection in the next week (HR 0.52, 95% CI 0.35–0.77, $p = 0.001$) (Table 2). Adding leucocyte count at $t = 0$, which was significant (Table 1), to the model platelet count remained a significant risk factor for infection (Table 2).

Platelet transfusion in ITP patients with and without infection

Ninety-one patients (58%) received one or more platelet transfusions during the first month of treatment, where 85% of the units were transfused within the first week (mean 4.6 ± 4.2 days after inclusion) (Table 1). At $t = 0$, there is a significant lower platelet count in the patient group who received a transfusion: $8.5 \times 10^9$/L versus $19.9 \times 10^9$/L ($p < 0.01$) (Fig. 3a). During the first month, there is no effect of platelet transfusion on platelet count ($p > 0.05$) (Fig. 3a). In the patients without infection, there is a positive, but not significant, trend of platelet transfusion on platelet count (Fig. 3b). In the patients with infection, there seems no effect of platelet transfusion on platelet count (Fig. 3c).

Discussion

The results of this large cohort reveals that an incidence of 24% in the first month of treatment infection is a common problem in patients with primary ITP. Additionally, patients with infection had a significant lower response rate at 1 month compared to patients without infection, possibly contributing to the significant longer hospital stay. Also, we could show that platelet count is correlated with infections and additionally that a low platelet count is an independent risk factor for infection within the next week with a hazard ration of 0.52. The role of platelet transfusion however remains unclear.

In the last years, more and more research has shown that platelets can modulate the innate and adaptive immune response. Especially for patients with sepsis, it is shown that thrombocytopenia is a surrogate marker for poor prognosis [6]. For patients with influenza infection, we could recently show that higher viral load leads to lower platelet counts and treatment with a sialidase inhibitor oseltamivir leads to higher platelet counts [12]. In the current study, we could show that infection is associated with lower response rates and longer hospital stay in patients with primary ITP. This might be due to the immunomodulatory treatment (e.g., steroids) patients received, although the average time of infection was 5.7 days after start of steroid therapy, making the role of treatment smaller in our study. Also, no difference in infection rate for dexamethasone or prednisone treatment was found. However, platelets can limit bacterial growth, influence leucocyte recruitment and functions, influence cytokine response, and

![Fig. 2](image-url)
influence activation of the vascular endothelium and coagulation system [8, 13–22]. Although the mechanism of these interactions is not fully understood, the expression of functional CD154 (CD40L) is a main contributor [23]. Interestingly, we could show that thrombocytopenia itself may be an independent and significant risk factor for infection, strengthening the role of platelets in infections.

Treatment of infections include antibiotic, antiviral, or antifungal therapies. To prevent infection-associated morbidity and mortality increase in platelet count, e.g., by prophylactic platelet transfusions might be the next step. In animal models, reinfusion of platelets to 10–15% of normal platelet count did prevent lung and brain bleeding during sepsis. As in theory, platelet transfusions can be given to prevent infections; during active infection, post-transfusion increments appear lower and more platelet transfusions are needed to maintain minimal numbers [24]. The beneficial effects of prophylactic platelet transfusion is uncertain and might be influenced by the state of the infection-induced response system [25]. Specifically in patients with ITP, prophylactic platelet transfusion is unclear and therefore however is not recommended, where in emergency cases, platelet transfusions can be given in combination with intravenous immunoglobulins (IVIg) [4, 26]. Our study is the first study providing data on platelet transfusion in ITP patients with and without infections. However, the primary indication for platelet transfusion remains still severe bleeding (risk) and prophylactic transfusion is therefore not recommended.

Acute bacterial or viral infections are known to cause ITP [5, 27]. First-line treatment of patients with ITP is steroids [2]. Next treatment options include for example splenectomy, TPO agonist, rituximab, and others. Treatment response is based on increase in platelet count to decrease risk of bleeding complications. However, according to our study, an increase in platelet count also leads to a reduction in infection. As mentioned before, platelet transfusion in patients with primary ITP is not recommended however, due to the low increments and risks of transfusion [2].

Limitations of our study are the retrospective nature of collection of data on infection as this was not the purpose of the randomized clinical trial. Secondly, infection was measured as CTC grade 2, thus with clinical symptoms. As we do not know the exact moment of inoculation, we could only use the time of clinical manifestation as outcome. Theoretically, as the thrombocytopenia occurs after the inoculation of the infection and the thrombocytopenia before the clinical presentation, thrombocytopenia could still be explained by the infection itself rather than being a risk factor. However, with the weekly intervals of platelet count measurements and the average inoculation time of the viral and bacterial infections, the relationship between low platelet count and risk of infections seems true. Additionally, there were no patients who had high platelet counts before time of infection. This weakens our Cox regression model with platelet count as time-dependent variable. Also, it is possible that the thrombocytopenia of some patients, thus the diagnosis ITP, might be a precursor sign of a hematological malignancy which have an increased risk of infections. Finally, due to the nature of our study design, we could only show a correlation and not an association between platelet count and infections. Further research is needed to confirm a possible association.

In conclusion, an incidence of 24% infection is a common complication in patient with primary immune thrombocytopenia leading to a worse response rate at 1 month and a longer hospital
stay. Low platelet count is correlated with increased risk of infections, strengthening the role of platelets in inflammation, but the role of platelet transfusion as therapeutic tool remains unclear. Further research is needed to investigate the exact mechanism of platelets in the inflammation process and the opportunity as therapeutic tool.

Authors’ contribution M.Q. and Q.L. are responsible for data collection, analyzing the data, and writing the manuscript. H.G.Z., J.P., and H.N. joined the international collaboration meetings and are responsible for designing the study and writing the manuscript. M.H. is responsible for designing the study, data collection, analyzing the data, and writing the manuscript, and A.J.G.J. is responsible for designing the study, analyzing the data, and writing the manuscript. All the authors approved the final manuscript.

Funding This work was supported by grants from the National Natural Science Foundation of China (No.81370623, No. 8147028), the Major Science Foundation of China (No.81370623, No. 8147028), the Major Funding

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Compliance with ethical standards

Authors

References

1. Liu X, Hou Y, Peng J (2013) Advances in immunopathogenesis of adult immune thrombocytopenia. Front Med 7:418–424
2. Rodeghiero F, Stasi R, Gershkesiner T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393
3. Portielje JE, Westendorp RG, Klum-Nelenmans HC, Brand A (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549–2554
4. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gershkesiner TB, Godeau B, Gaininger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115:168–186
5. Ekstrand C, Linder M, Cheri F, Kieler H, Bahmanyar S (2016) Increased susceptibility to infections before the diagnosis of immune thrombocytopenia. J Thromb Haemost 14:807–814
6. Claushuis TA, van Vught LA, Secliluna BP et al (2016) Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood 127:3062–3072
7. Golebiewska EM, Poole AW (2015) Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev 29:153–162
8. Semple JW, Italiano Jr JE, Freedman J (2011) Platelets and the immune continuum. Nat Rev Immunol 11:264–274
9. Smyth HS, McEvoy RP, Weyrich AS et al (2009) Platelet functions beyond hemostasis. J Thromb Haemost 7:1759–1766
10. Tang T, Liu Z, Wang Z, Duan M, Li G, Wang S, Li W, Zhu Z, Wei Y, Christian Li, A, Zhu X (2014) Thrombocytopenia is associated with acute respiratory distress syndrome mortality: an international study. PLoS One 9:e94124
11. Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, Liu GQ, Peng J, Hou M (2016) High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood 127:296–302
12. Jansen AJG, Peng J, Zhao HG, Hou M, Ni H (2015) Sialidase inhibition to increase platelet counts: a new treatment option for thrombocytopenia. Am J Hematol 90:E94–E95
13. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, Keys EM, Allen–Vercoe E, DeVinney R, Doig CJ, Green FH, Kubes P (2007) Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13:463–469
14. Doyle VS, Bergmeier W, Mitchell HA, Eichenberger SC, Wagner DD (2005) Activated platelets induce Weibel–Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood 106:2334–2339
15. Fujijsi S, MacComnara MP, Maung AA, Zang Y, Mannick JA, Lederer JA, Lapchak PH (2009) Platelet depletion in mice increases mortality after thermal injury. Blood 107:4399–4406
16. Goerge T, Ho-Tin-Noe B, Carbo C, Benarab C, Remold-O’Donnell E, Zhao BQ, Cifuni SM, Wagner DD (2008) Inflammation induces hemorrhage in thrombocytopenia. Blood 111:4958–4964
17. Hara T, Shimizu K, Ogawa F, Yanaka K, Iwata Y, Muroi E, Takenaka M, Komura K, Hasegawa M, Fujimoto M, Sato S (2010) Platelets control leukocyte recruitment in a murine model of cutaneous arthus reaction. Am J Pathol 176:259–269
18. Inui M, Tazawa K, Kishi Y, Takai T (2015) Platelets convert peripheral blood circulating monocytes to regulatory cells via immunoglobulin G and activating-type Fcγ receptors. BMC Immunol 16:20
19. Mackman N, Tilley RE, Key NS (2007) Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 27:1687–1693
20. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P (2012) Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 12:323–334
21. de Stoppelaar SF, van Veer C, Claushuis TAM et al (2014) Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice. Blood 124:3781–3790
22. Xiang B, Zhang G, Guo L et al (2013) Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun 4:2657
23. Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL (2008) Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 111:5028–5036
24. Levi M, Opal SM (2006) Coagulation abnormalities in critically ill patients. Crit Care 10:222
25. Speth C, Löffler J, Krappmann S, Lassa-Flörl C, Rambach G (2013) Platelets as immune cells in infectious diseases. Future Microbiol 8:1451–1458
26. Guo L, Yang L, Speck ER, Aslam R, Kim M, McKenzie CJJ, Lazarus AH, Ni H, Hou M, Freedman J, Semple JW (2014) Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia. Blood 123:422–427
27. Cines DB, Cuker A, Semple JW (2014) Pathogenesis of immune thrombocytopenia. Presse Med 43:e49–e59